Company intelligence / Profile preview

RegeneRx Biopharmaceuticals, Inc.

Rockville, Maryland, United Statesregenerx.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 3

Overview

RegeneRx’s lead candidate RGN-259 has completed multiple Phase III trials for dry eye disease and neurotrophic keratitis. While some trials did not meet all primary endpoints for DED, statistically significant improvements were observed in symptoms. For NK—a rare orphan indication—RGN-259 demonstrated efficacy in a small initial Phase III trial with ongoing pivotal studies underway in the US and Europe. Other programs are at various clinical stages targeting wound healing and cardiovascular/neurological indications.

Therapeutic areas: DermatologyCardiovascularOphthalmologyNeurology
Modalities: Peptides (notably Thymosin beta 4 and its derivatives)
Industry: Biotech

Drug pipeline

1 asset

thymosin beta-4

Partnerships

Lee’s Pharmaceutical Group (Asia)HLB Therapeutics/ReGenTree LLC joint venture (US/EU ophthalmology)

Beyond the preview

Go deeper on RegeneRx Biopharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RegeneRx Biopharmaceuticals, Inc..